T1	intervention 29 33	Talc
T2	intervention 41 53	Iodopovidone
T3	condition 76 92	Seroma Formation
T4	eligibility 560 626	Patients with breast cancer undergoing modified radical mastectomy
T5	control 680 687	control
T6	outcome-Measure 756 785	frequency of seroma formation
T7	outcome-Measure 815 834	wound complications
T12	total-participants 985 987	86
T13	total-participants 1022 1024	80
T14	outcome 1126 1142	adverse outcomes
T15	outcome 1092 1104	discontinued
T17	iv-bin-percent 1303 1308	19.4%
T18	cv-bin-percent 1328 1333	23.3%
T9	outcome 1431 1461	aspirations per patient seroma
T10	outcome 1471 1485	volume drained
T11	outcome 1285 1301	seroma formation
T16	iv-cont-mean 1524 1528	88.2
T19	iv-cont-sd 1531 1533	73
T20	cv-cont-mean 1538 1543	158.3
T21	cv-cont-sd 1546 1550	90.5
T8	outcome-Measure 899 912	analgesic use
T22	outcome-Measure 914 932	postoperative pain
T23	outcome-Measure 934 953	total drain outputs
T24	outcome-Measure 959 976	drainage duration
T25	outcome 1144 1161	drainage duration
T26	outcome 1166 1195	total amount of fluid drained
